Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | NEK1 | Q96PY6 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730176 | 0.84 | MKNK2 (0.55) | MKNK1MKNK2CDK8GRM5ABL1 | |
| SCHEMBL418337 | 0.83 | SLC40A1 (0.57) | ALDH1A1HPGDL3MBTL1NPC1RAB9A | |
| SCHEMBL15730264 | 0.83 | MKNK1 (0.51) | MKNK1MKNK2CDK8SCN5ASCN9A | |
| SCHEMBL15730523 | 0.82 | MKNK1 (0.70) | MKNK1MKNK2NPC1RAB9ACDK8 | |
| SCHEMBL2083887 | 0.82 | ERN1 (0.52) | ALDH1A1HPGDL3MBTL1NPC1RAB9A | |
| SCHEMBL5558179 | 0.82 | CDK8 (0.56) | ALDH1A1HPGDL3MBTL1NPC1RAB9A | |
| SCHEMBL27597178 | 0.81 | MKNK1 (0.49) | MKNK1MKNK2ABL1SCN5ASCN9A | |
| SCHEMBL21819238 | 0.80 | MKNK1 (0.49) | ALDH1A1HPGDL3MBTL1MKNK1MKNK2 | |
| SCHEMBL15730268 | 0.80 | MTOR (0.58) | MKNK1MKNK2ERN1SCN5ASCN9A | |
| SCHEMBL16749656 | 0.80 | CA12 (0.58) | NPC1RAB9AAXLNEK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978200-B | Biphenylamide derivative, preparation method and application | 湖北省生物农药工程研究中心 | 2022-09-13 | — | — | CN | disclosed |
| CN-111978200-A | Bibenzamide derivative and preparation method and application thereof | 湖北省生物农药工程研究中心 | 2020-11-24 | — | — | CN | disclosed |
| CN-105073751-B | The substituted imidazoles new as Casein kinase 1 δ/epsilon inhibitor | 百时美施贵宝公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-105073751-A | Novel substituted imidazoles as casein kinase 1 [delta]/[epsilon] inhibitors | BRISTOL MYERS SQUIBB CO | 2015-11-18 | — | — | CN | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | ALDH1A1 314/4885HPGD 237/4885L3MBTL1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.